Clinical trial
Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus…
NCT00109655 · Cell Genesys, Industry · Unknown status
Key facts
| NCT number | NCT00109655 |
|---|---|
| Title | Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure |
| Official title | A Phase 1 Dose-Escalation Trial of Intravesical CG0070 for Superficial Transitional Cell Carcinoma of the Bladder After Bacillus Calmette-Guerin Failure |
| Lead sponsor | Cell Genesys, Industry |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Carcinoma, Transitional Cell, Bladder Neoplasms |
| Intervention type | Biological |
| Interventions | Oncolytic adenovirus (serotype 5) - CG0070 |
| Enrollment | 75 |
| Start date | Apr 1, 2005 |
| Primary completion | Oct 1, 2008 |
| Completion | Sep 1, 2010 |
| First posted | May 3, 2005 |
| Last update posted | Oct 3, 2008 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: